Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 21 for “"Abemaciclib"”.

  1. A Novel High-Throughput Screen Identifies Abemaciclib as a Potent Inducer of Physiologic Hypertrophy and Cardioprotection

    … The screen identified the CDK4/CDK6 inhibitor abemaciclib (LY2835219), a clinically prescribed anti-cancer agent, as a potent PhCH remodeling cue in both rodent cardiomyocytes and human iPSC-derived cardiomyocytes. siRNA-targeted inhibition of CDK4 expression phenocopied abemaciclib treatment …

    ottawa-retro Repository record for A Novel High-Throughput Screen Identifies Abemaciclib as a Potent Inducer of Physiologic Hypertrophy and Cardioprotection (opens in a new tab)

  2. Zielgerichtete Therapien beim Mantelzelllymphom

    … to cell cycle progression from G1- into S-phase. Abemaciclib is a novel potent small molecule CDK4/6 inhibitor and therefore poses a rational approach in MCL therapy. In this study we evaluated the effect of abemaciclib as a single agent and in combination therapy with inhibitors of the BCR …

    lmu-germany Repository record for Zielgerichtete Therapien beim Mantelzelllymphom (opens in a new tab)

  3. COMBINATION TREATMENT OF MEK AND CDK4/6 INHIBITORS IN THE AGGRESSIVE PEDIATRIC BRAIN TUMOR ATRT

    … penetrant cyclin dependent kinase 4/6 inhibitor abemaciclib further suppressed growth and BrdU incorporation in ATRT cell lines representing all molecular subgroups. Mirdametinib and abemaciclib combined to extend survival of mice bearing orthotopic ATRT xenografts. In conclusion, mirdametinib …

    jhu Repository record for COMBINATION TREATMENT OF MEK AND CDK4/6 INHIBITORS IN THE AGGRESSIVE PEDIATRIC BRAIN TUMOR ATRT (opens in a new tab) Embargoed until 2029-05-01

  4. The use of KRAS and CDK inhibitors in the treatment of brain metastases in pre-clinical models

    … adagrasib (MRTX849), a KRAS G12C inhibitor, and abemaciclib, a CDK 4/6 inhibitor, both individually and in combination against BMs originating from NSCLC cell lines harboring KRAS G12C and CDKN2A mutations. Utilizing a diverse array of methodologies encompassing cell viability assays, cell death …

    bu Repository record for The use of KRAS and CDK inhibitors in the treatment of brain metastases in pre-clinical models (opens in a new tab)

  5. Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer

    … of CDK4/6, namely palbociclib, ribociclib and abemaciclib, have been approved by the US FDA for the treatment of advanced metastatic oestrogen-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer in combination with antioestrogens. Abemaciclib has also been …

    adelaide Repository record for Preclinical evaluation of inhibitors of cyclin-dependent kinases 4 and 6 for the treatment of cancer (opens in a new tab)

  6. Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells

    … we add another Cdk4/6 inhibitor to the model, abemaciclib, which can induce apoptosis at high concentrations. Then the model can match the effects of abemaciclib treatment at two different doses and also capture the apoptosis effects induced by abemaciclib. After calibrating the model to these …

    vt Repository record for Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells (opens in a new tab)

  7. Delivery And Efficacy Of CDK4/6 Inhibitors In The Treatment Of Brain Tumors

    … CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib, currently in clinical development for the treatment of a variety of solid tumors. We show that palbociclib has limited brain delivery to active efflux transport by P-gp and BCRP at the BBB. Furthermore, we demonstrate that the …

    umn Repository record for Delivery And Efficacy Of CDK4/6 Inhibitors In The Treatment Of Brain Tumors (opens in a new tab)

  8. Cyclin Dependent Kinase 4/6 as a Therapeutic Target in the Treatment of Glioblastoma

    … FDA-approved small molecule inhibitors including abemaciclib, ribociclib, and palbociclib, initially approved for breast cancer, shows promise in Glioblastoma treatment. However, a poor GBM clinical trial track necessitates the identification of predictive markers to enhance treatment outcomes. …

    wayne-thes Repository record for Cyclin Dependent Kinase 4/6 as a Therapeutic Target in the Treatment of Glioblastoma (opens in a new tab)

  9. Carbon Nano-Onions for Theragnostic Applications

    … of anticancer drugs Doxorubicin (DOX) and Abemaciclib (Abema) were then studied. The systems were characterised via microscopic and spectroscopic analysis and the cytotoxicity and cellular uptake of the DOX nanocarrier system was tested on triple-negative breast cancer cells. The …

    dcu Download PDF for Carbon Nano-Onions for Theragnostic Applications (opens in a new tab) Embargoed until 2029-10-01

  10. NOVEL HER2 MUTATIONS CONFER ENDOCRINE RESISTANCE IN ER+ HER2- BREAST CANCER

    … partially overcome by the novel CDK4/6 inhibitor abemaciclib, and completely resolved with the second-generation tyrosine kinase inhibitor neratinib.

    jhu Repository record for NOVEL HER2 MUTATIONS CONFER ENDOCRINE RESISTANCE IN ER+ HER2- BREAST CANCER (opens in a new tab) Embargoed until 2028-05-01

  11. Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer

    … observations showing that FDA-approved CDK4/6i Abemaciclib (Abe) inadvertently activates STAT3 in TNBC, we proposed a novel treatment regimen by combining Abe with an FDA-approved JAK2-specific inhibitor Fedratinib (Fed) to enhance Abe’s efficacy in TNBC. For the first time, our study …

    uthsc Repository record for Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer (opens in a new tab)

  12. Characterization of Dysregulated VHL-Mediated pRb Regulation in Clear Cell Renal Cell Carcinoma

    … interaction between the CDK4/6 inhibitor Abemaciclib and the E2F1 activator β-lapachone, resulting in decreased viability across various ccRCC cell lines. While these results suggest a promising therapeutic approach, in vivo validation remains necessary. Overall, my work uncovers a …

    ottawa-retro Repository record for Characterization of Dysregulated VHL-Mediated pRb Regulation in Clear Cell Renal Cell Carcinoma (opens in a new tab)

  13. Οι νεότερες εξελίξεις στον καρκίνο του μαστού-οι αλλαγές στο θεραπευτικό αλγόριθμο

    … σημαντικά την πρόγνωση. Οι αναστολείς CDK4/6 (abemaciclib, ribociclib) προσφέρουν αυξημένη επιβίωση όχι μόνο στη μεταστατική αλλά και στην πρώιμη νόσο υψηλού κινδύνου. Οι αναστολείς PARP όπως το olaparib έχουν θέση σε ασθενείς με μεταλλάξεις BRCA1/2, ενώ καινούργιοι HER2-στοχευμένοι παράγοντες …

    athens Repository record for Οι νεότερες εξελίξεις στον καρκίνο του μαστού-οι αλλαγές στο θεραπευτικό αλγόριθμο (opens in a new tab)

  14. Development of CDK4/6 Inhibitor Resistant ER-positive HER2-negative Breast Cancer Cell Lines to Elucidate Novel Mechanisms of Resistance

    … resistance to two CDK4/6i, palbociclib and abemaciclib, using MCF7 and T47D cell lines. Genomic, transcriptomic, and proteomic analyses were performed in parental cells and resistant derivatives. Strikingly, acquired resistance across all models was associated with an upregulated interferon …

    toronto-retro Repository record for Development of CDK4/6 Inhibitor Resistant ER-positive HER2-negative Breast Cancer Cell Lines to Elucidate Novel Mechanisms of Resistance (opens in a new tab)

  15. Simultaneous Targeting of CDK4/6 and BETs is Independent of RB Status in Osteosarcoma

    … inhibitors (CDK4/6i), like palbociclib and abemaciclib, as promising therapeutic strategies. However, monotherapy often fails, highlighting the need for effective combination approaches. While functional RB has traditionally been viewed as necessary for CDK4/6i sensitivity, emerging evidence …

    iupui Repository record for Simultaneous Targeting of CDK4/6 and BETs is Independent of RB Status in Osteosarcoma (opens in a new tab)

  16. Η θέση των αναστολέων κυκλινοεξαρτώμενων κινασών 4/6 (CDK4/6 inhibitors) στη θεραπευτική αντιμετώπιση του ορμονοευαίσθητου, HER2- αρνητικού (HR+/HER2-) μεταστατικού καρκίνου μαστού

    … δεδομένα συνολικής επιβίωσης, ενώ το abemaciclib ξεχωρίζει λόγω της συνεχούς αναστολής της οδού και της αποτελεσματικότητάς της σε βιολογικά πιο επιθετικές μορφές της νόσου. Παρά τα σημαντικά αποτελέσματα από τη χρήση τους, η ανάπτυξη αντοχής στους αναστολείς CDK4/6 παραμένει …

    athens Repository record for Η θέση των αναστολέων κυκλινοεξαρτώμενων κινασών 4/6 (CDK4/6 inhibitors) στη θεραπευτική αντιμετώπιση του ορμονοευαίσθητου, HER2- αρνητικού (HR+/HER2-) μεταστατικού καρκίνου μαστού (opens in a new tab)

  17. Targeting Transcription Factors in Neuroblastoma: Development of Aurora Kinase A/N-Myc Degraders and ID2 Chemical Probes

    … serendipitous discovery of 6.1 (HLB-0534981), an abemaciclib analogue, that induces a potent downregulation of both ID2 and N-Myc. To decipher the unknown target(s) of 6.1, a diazirine photo-crosslinking probe, 6.6 (HLB-0535030), has been successfully developed and validated as a viable probe for …

    umn Repository record for Targeting Transcription Factors in Neuroblastoma: Development of Aurora Kinase A/N-Myc Degraders and ID2 Chemical Probes (opens in a new tab)

  18. Healthcare resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with CDK4/6i in the first-line setting

    … inhibitors (palbociclib, ribociclib, and abemaciclib) has transformed the treatment landscape for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). To our knowledge, no studies have quantified …

    washington Repository record for Healthcare resource utilization and costs of Medicare-enrolled patients with HR+/HER2- metastatic breast cancer treated with CDK4/6i in the first-line setting (opens in a new tab)

  19. Utilization of anticancer medicines and breast cancer mortality in lithuania /

    … pertuzumab combined with trastuzumab, and abemaciclib, increased between 2019 and 2024. Older age was associated with lower odds of receiving chemotherapy, targeted therapy, radiotherapy, and surgery, while metastatic disease was associated with higher use of systemic therapies. Mortality …

    vilnius Repository record for Utilization of anticancer medicines and breast cancer mortality in lithuania / (opens in a new tab)

  20. Desarrollo de la aplicabilidad clínica y farmacoeconómica del análisis por subgrupos según la medicina basada en la evidencia

    … parte fueron pembrolizumab en cáncer de pulmón, abemaciclib en cáncer de mama, la combinación de nivolumab más ipilimumab en varios tipos de cáncer, y remdesivir en COVID-19. La herramienta demostró que puede evitar un impacto negativo de afirmaciones erróneas sobre los resultados de subgrupos en …

    sevilla Repository record for Desarrollo de la aplicabilidad clínica y farmacoeconómica del análisis por subgrupos según la medicina basada en la evidencia (opens in a new tab)

Page 1 of 2